Sharma, R. A., Plummer, R., Stock, J. K., Greenhalgh, T. A., Ataman, O., Kelly, S., Clay, R., Adams, R. A., Baird, R. D., Billingham, L., Brown, S. R., Buckland, S., Bulbeck, H., Chalmers, A. J., Clack, G., Cranston, A. N., Damstrup, L., Ferraldeschi, R., Forster, M. D., Golec, J., Hagan, R. M., Hall, E., Hanauske, A. R., Harrington, K. J., Haswell, T., Hawkins, M. A., Illidge, T., Jones, H., Kennedy, A. S., McDonald, F., Melcher, T., O'Connor, J. P. B., Pollard, J. R., Saunders, M. P., Sebag-Montefiore, D., Smitt, M., Staffurth, J., Stratford, I. J., Wedge, S. R., Worki, Ncri CTRad Acad-Pharma Joint (2016) Clinical development of new drug-radiotherapy combinations. NATURE REVIEWS CLINICAL ONCOLOGY, 13 (10). pp. 627-642. ISSN 1759-4774

Preview

Text 15387.pdf Download (469kB) | Preview

Abstract

In countries with the best cancer outcomes, approximately 60% of patients receive radiotherapy as part of their treatment, which is one of the most cost-effective cancer treatments. Notably, around 40% of cancer cures include the use of radiotherapy, either as a single modality or combined with other treatments. Radiotherapy can provide enormous benefit to patients with cancer. In the past decade, significant technical advances, such as image-guided radiotherapy, intensity-modulated radiotherapy, stereotactic radiotherapy, and proton therapy enable higher doses of radiotherapy to be delivered to the tumour with significantly lower doses to normal surrounding tissues. However, apart from the combination of traditional cytotoxic chemotherapy with radiotherapy, little progress has been made in identifying and defining optimal targeted therapy and radiotherapy combinations to improve the efficacy of cancer treatment. The National Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group (CTRad) formed a Joint Working Group with representatives from academia, industry, patient groups and regulatory bodies to address this lack of progress and to publish recommendations for future clinical research. Herein, we highlight the Working Group's consensus recommendations to increase the number of novel drugs being successfully registered in combination with radiotherapy to improve clinical outcomes for patients with cancer.

Item Type:	Article
Authors (ICR Faculty only):	Harrington, Kevin
All Authors:	Sharma, R. A., Plummer, R., Stock, J. K., Greenhalgh, T. A., Ataman, O., Kelly, S., Clay, R., Adams, R. A., Baird, R. D., Billingham, L., Brown, S. R., Buckland, S., Bulbeck, H., Chalmers, A. J., Clack, G., Cranston, A. N., Damstrup, L., Ferraldeschi, R., Forster, M. D., Golec, J., Hagan, R. M., Hall, E., Hanauske, A. R., Harrington, K. J., Haswell, T., Hawkins, M. A., Illidge, T., Jones, H., Kennedy, A. S., McDonald, F., Melcher, T., O'Connor, J. P. B., Pollard, J. R., Saunders, M. P., Sebag-Montefiore, D., Smitt, M., Staffurth, J., Stratford, I. J., Wedge, S. R., Worki, Ncri CTRad Acad-Pharma Joint
Additional Information:	ISI Document Delivery No.: DX3CK Times Cited: 0 Cited Reference Count: 155 Sharma, Ricky A. Plummer, Ruth Stock, Julie K. Greenhalgh, Tessa A. Ataman, Ozlem Kelly, Stephen Clay, Robert Adams, Richard A. Baird, Richard D. Billingham, Lucinda Brown, Sarah R. Buckland, Sean Bulbeck, Helen Chalmers, Anthony J. Clack, Glen Cranston, Aaron N. Damstrup, Lars Ferraldeschi, Roberta Forster, Martin D. Golec, Julian Hagan, Russell M. Hall, Emma Hanauske, Axel-R. Harrington, Kevin J. Haswell, Tom Hawkins, Maria A. Illidge, Tim Jones, Hazel Kennedy, Andrew S. McDonald, Fiona Melcher, Thorsten O'Connor, James P. B. Pollard, John R. Saunders, Mark P. Sebag-Montefiore, David Smitt, Melanie Staffurth, John Stratford, Ian J. Wedge, Stephen R. Sirtex Technology; Affidea; BTG plc; Cancer Research Technology; Sirtex Medical; Vertex; AstraZeneca; Medimmune; Roche; Astex Pharmaceuticals R.A.S. has received research funding from Sirtex Technology and consultation fees from Affidea, BTG plc, Cancer Research Technology, Sirtex Medical, and Vertex. O.A. is an employee of Eisai. S. K. and S. B. are employees of Pfizer Ltd. L.B. has received honorarium from Eli Lilly, Pfizer and Roche. G.C. is an employee and shareholder of AstraZeneca. A.N.C. is an employee and stockholder of MISSION therapeutics. L.D. is an employee of Merck KGaA. R.F. is an employee of Astex Pharmaceuticals. J.G. is an employee of Vertex Pharmaceuticals (Europe) Ltd and owns shares in Vertex Pharmaceuticals Inc. R.M.H. is an employee of BTG International Ltd, a manufacturer of specialist healthcare products. A.-R.H. is an employee and stock holder of Eli Lilly. T.I. receives research support from AstraZeneca, Medimmune and Roche. T.M. is an employee of Johnson & Johnson. J.R.P. is an employee of, and holds stock in, Vertex Pharmaceuticals. M.S. is an employee of Genentech and stockholder of Roche. I.J.S. is a recipient of a research grant from AstraZeneca. S.R.W. receives research funding from Astex Pharmaceuticals and AstraZeneca. R.P., J.K.S., T.A.G., R.C., R.A.A., R.D.B., S.R.B., H.B., A.J.C., M.D.F., E.H., K.J.H., T.H., M.A.H., H.J., A.S.K., F.M., J.P.B.O'C., M.P.S., D.S.-M. and J.S. declare no competing interests. 0 1 NATURE PUBLISHING GROUP NEW YORK NAT REV CLIN ONCOL
Uncontrolled Keywords:	CELL LUNG-CANCER SURROGATE END-POINTS ADVANCED RECTAL-CANCER POSITRON-EMISSION-TOMOGRAPHY MOLECULARLY TARGETED AGENTS III RANDOMIZED-TRIAL EARLY BREAST-CANCER PHASE-I TRIALS RADIATION-THERAPY PROSTATE-CANCER
Research teams:	ICR divisions > Cancer Biology > Targeted Therapy ICR divisions > Radiotherapy and Imaging > Targeted Therapy Clinical Units > Head & Neck Cancer Unit
Depositing User:	Barry Jenkins
Date Deposited:	24 Oct 2016 14:21
Last Modified:	24 Oct 2016 14:25
URI:	http://publications.icr.ac.uk/id/eprint/15387

Actions (login required)

View Item